A Multinational, Multicenter, Randomized, Parallel-group Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Assess Efficacy, Safety and Tolerability of Glatiramer Acetate Injection 40mg Compared to Placebo in a Double-blind Design

Trial Profile

A Multinational, Multicenter, Randomized, Parallel-group Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Assess Efficacy, Safety and Tolerability of Glatiramer Acetate Injection 40mg Compared to Placebo in a Double-blind Design

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms GALA
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 29 Jun 2017 This trial has been completed in Hungary (end date: 12 May 2017) and Estonia (end date: 12 May 2017).
    • 15 Jun 2017 This trial has been completed in Bulgaria (end date: 12 May 2017).
    • 30 Apr 2017 This trial has been completed in Lithuania.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top